

SPANISH ASSOCIATION OF PAEDIATRICS

Consensus document of the SEIP/AEPap/SEPEAP/SEGHNP/SEUP on the diagnosis and etiological treatment of infectious acute gastroenteritis



Alicia Berghezan-Suárez^{a,b,*}, David López-Martín^b, Ángel José Carbajo Ferreira^a, Parísá Khodayar-Pardo^c, Luis Ortiz González^d, Belén Aguirrezabalaga González^d, Ricardo Torres-Peral^e, Roi Piñeiro Pérez^b, María Natali Campo Fernández^c, Begoña Pérez-Moneo^e, Grupo de Trabajo de Gastroenteritis Aguda en Pediatría¹

^a Asociación Española de Pediatría de Atención Primaria (AEPap), Spain

^b Sociedad Española de Infectología Pediátrica (SEIP), Spain

^c Sociedad Española de Urgencias de Pediatría (SEUP), Spain

^d Sociedad Española de Pediatría Extrahospitalaria y de Atención Primaria (SEPEAP), Spain

^e Sociedad Española de Gastroenterología, Hepatología y Nutrición Pediátrica (SEGHNP), Spain

Received 31 May 2025; accepted 21 July 2025

Available online 17 October 2025

KEYWORDS

Acute;
Gastroenteritis;
Consensus;
Salmonella;
E coli;
Post-enteritis
syndrome

Abstract Acute gastroenteritis (AGE) is a leading cause of morbidity and mortality in pediatric patients worldwide. Microbiological testing of AGE is reserved for prolonged or complicated cases and for patients with certain risk factors. Diagnostic tests should be selected based on availability and the clinical and epidemiological context. The following tests could be requested, depending on the suspected diagnosis: stool or blood culture, rapid tests, molecular tests, ova and parasite test or serology. Complete blood counts and acute phase reactant (APR) tests are indicated in patients with signs of severe disease. Sociodemographic and climate changes have led to an increase in the incidence of pathogens previously rare in our region (emerging pathogens), which must also be considered. Microorganisms of uncertain significance may also be detected, which should either not be treated or treated only under specific circumstances. In general, empirical antibiotherapy should not be initiated for management of AGE

DOI of original article: <https://doi.org/10.1016/j.anpedi.2025.503984>

* Corresponding author.

E-mail address: abergsua@gmail.com (A. Berghezan-Suárez).

¹ The numbers of the components of the Gastroenteritis and Pediatric Work Group are listed in Annex 1.

PALABRAS CLAVE

Gastroenteritis
aguda;
Consenso;
Salmonella;
E. coli;
Postenteritis

except in specific situations: infants aged less than 3–6 months with suspected bacterial AGE, patients with underlying disease, signs of sepsis, institutionalized patients or settings with risk of dissemination. In cases of AGE caused by non-Typhi *Salmonella* and Shiga toxin-producing *Escherichia coli* (STEC), targeted antibiotherapy is restricted to patients at risk of systemic infection or with prolonged diarrhea. In Spain, complications of AGE are rare, and dehydration and post-enteritis syndrome are most common.

© 2025 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Documento consenso SEIP/AEPap/SEPEAP/SEGHNP/SEUP sobre el diagnóstico y tratamiento etiológico de las gastroenteritis agudas de origen infeccioso

Resumen La gastroenteritis aguda (GEA) es una importante causa de morbi-mortalidad a nivel mundial en la edad pediátrica. El estudio microbiológico de los cuadros de GEA se reserva a procesos prolongados o complicados así como a pacientes con determinados factores de riesgo. Los métodos diagnósticos deben seleccionarse en función de la disponibilidad de los mismos y del contexto clínico y epidemiológico. En función de la sospecha diagnóstica pueden solicitarse: cultivo de heces o sangre, técnicas de detección rápida, técnicas moleculares, examen fresco en heces o serologías. El hemograma y los reactantes de fase aguda (RFA) están indicados cuando el paciente presenta signos de gravedad. Los cambios socio-demográficos y climatológicos han propiciado el aumento de la incidencia de patógenos infrecuentes en nuestro entorno (emergentes) y, que por lo tanto, también deben de tenerse en consideración. Así mismo, pueden detectarse microorganismos de significado incierto, y que o no deben tratarse o sólo en circunstancias concretas. Generalmente, ante un cuadro de GEA no debe iniciarse antibioterapia de forma empírica salvo en determinadas situaciones: lactantes menores de 3–6 meses con sospecha de GEA de origen bacteriano, existencia de una enfermedad de base, signos de sepsis y en contextos de institucionalización o con riesgo de diseminación. En los casos de GEA por *Salmonella no typhi* y de *Escherichia coli* productora de toxina shiga (STEC) la antibioterapia dirigida se restringe a los casos de riesgo de infección sistémica o de diarrea prolongada. En nuestro medio, las complicaciones de la GEA son poco frecuentes, destacando la deshidratación y el síndrome postenteritis.

© 2025 Asociación Española de Pediatría. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la CC BY-NC-ND licencia (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Acute gastroenteritis (AGE) is defined as a decrease in the consistency of stools (loose or liquid) and/or an increase in the frequency of evacuations (typically ≥ 3 in 24 h), with or without fever or vomiting, typically lasting less than 7 days and no more than 14 days.¹

Globally, diarrheal diseases are the third leading cause of death in children younger than 5 years.² In countries with a high human development index (HDI), although the mortality of diarrheal diseases is low, the morbidity is high and has a substantial social and economic impact.³ Acute gastroenteritis is also one of the main health care-associated infections.¹

In Europe, the incidence of AGE is estimated at 0.5–2 episodes per child per year in children younger than 3 years. Rotavirus is the most frequently involved pathogen, causing up to 1.33–4.96 AGE cases/100 person year, followed by norovirus. This trend is inverted in countries with a high rotavirus vaccination coverage.¹

Table 1 presents the cumulative incidence of the different notifiable causative organisms of AGE in Spain.

This document focuses on the diagnosis and etiological treatment of AGE in the pediatric population, as well as its possible complications. With the aim of producing a practical and useful document, we structured it as a series of questions answered by the authors.

Methods

Working group

A working group (WG) was constituted in 2024 to draft this consensus document, comprising representatives from the main pediatric societies involved in the care and management of children with AGE in Spain: Sociedad Española de Infectología Pediátrica (SEIP), Asociación Española de Pediatría de Atención Primaria (AEPap), Sociedad Española de Pediatría Extrahospitalaria y Atención Primaria (SEPEAP),

Table 1 Cumulative incidence of gastroenteritis caused by microorganisms subject to mandatory reporting in Spain in 2022/National Epidemiological Surveillance Network.

Microorganism	Incidence per 100 000 inhabitants	Age peak
<i>Campylobacter</i> spp	59.16 cases	<5 years
<i>Salmonella</i> (enteritidis, typhimurium, virchow)	24.97 cases	<5 years
<i>Giardia</i> (lamblia/duodenalis)	7.42 cases	<5 years
<i>Yersinia</i> (enterocolitica and pseudotuberculosis)	2.32 cases	<5 years
<i>Cryptosporidium</i> (hominis and parvuum)	1.84 cases	<5 years
Verotoxigenic <i>E coli</i>	1.36 cases	<5 years
<i>Shigella</i> spp	1.14 cases	girls: <10 years boys: 20–44 years
Typhoid fever (<i>Salmonella typhi</i> and <i>paratyphi</i>)	0.05 cases	1–14 years
Outbreaks involving emerging pathogens		
<i>Cryptosporidium</i> 2023 ^a (<i>hominis</i> and <i>parvuum</i>)	8.3 cases	1–4 years

^a Data for 2022 not available.

Sociedad Española de Gastroenterología, Hepatología y Nutrición Pediátrica (SEGHNP) and Sociedad Española de Urgencias Pediátricas (SEUP). Two authors and one or two reviewers were requested from each society. The WG was finally composed of the members listed in Appendix B.

Development of the consensus document

After the WG was formed, the group proceeded to define the sections of the document, and two to three authors from different societies were assigned to draft each section based on their expertise and field of work. Similarly, two reviewers were assigned to each section, who, to the extent possible, were selected among the members of societies other than those of the authors.

The author groups conducted an initial literature search, based on which they proposed 15 questions in pursuit of the objective of the document. These questions, as well as the structure of the document (tables, figures, number of words, etc), were agreed upon by all authors. Subsequently, based on a second literature search focused on the questions formulated in the previous step, each group produced a draft of their section to be presented to the other authors. Initial recommendations were also drafted. After an initial analysis and discussion of the text, a document was developed by consensus and sent, divided by sections, to the corresponding reviewers. A final draft was produced by integrating the corrections and proposals of reviewers and submitted in its entirety (text, tables, figures, and appendices) for review by all members of the WG. Last of all, the WG voted on the proposed recommendations.

Literature search

A literature search was conducted in PubMed® with additional searches for guidelines published by Spanish, European and United States pediatric societies, prioritizing articles published in the last 10 years (between 2014 and 2024) and focused, whenever possible, on the pediatric pop-

ulation (0–18 years). Articles published before 2014 were included if there were no subsequent publications on the subject at hand. The references can be found at the end of the document, and sources used in the tables in Appendix B 3.

The selected articles were reviewed by each corresponding author and included in the consensus document if the information could be used to answer any of the formulated questions. The group did not conduct a systematic assessment of the quality of the evidence.

Final recommendations

After the final review of the entire document by all members of the WG, the recommendations derived from the consensus document were subject to an anonymous vote in which each WG member had to express the degree of agreement with each recommendation (agreement, disagreement or abstention). If there was disagreement, recommendations were modified, always with the goal of achieving consensus in at least 80% of the members. Appendix B 2 presents the results of the vote, specifying the rationales expressed in cases of disagreement and the modifications made as a result.

Diagnosis

In a child with acute gastroenteritis, when is it appropriate to perform microbiological stool testing?

Identifying the causative agent provides epidemiological and prognostic information, can guide decision-making in regard to the indication of antibiotherapy and, if appropriate, can help select the most suitable drug through antimicrobial susceptibility testing.⁴

Microbiological investigations are not usually necessary, as most cases of AGE are mild, self-limiting and viral. Table 2 presents the indications for microbiological testing.^{4,5}

Table 2 Diagnosis: indications for microbiological investigation.

Stool testing	Blood culture
• Duration of symptoms >7 days • Severe disease requiring hospitalization • Risk of complications: - Age less than 3 months - Immunocompromised status - Oncological disease - Inflammatory bowel disease - Other chronic diseases • Nosocomial diarrhea • Suspected invasive enteric diarrhea (high fever, bloody diarrhea) • Suspected hemolytic uremic syndrome • Outbreak in school, hospital or family • Recent travel to an endemic area	• Signs of sepsis • Suspected enteric fever • Immunocompromised status • High risk of hemolytic anemia • Age less than 3 months AND symptoms of inflammatory diarrhea or dysentery syndrome

Specifically, based on the type of microorganism: when is it appropriate to test for bacteria, viruses or parasites in stool? When is it appropriate to perform blood culture?

Testing for bacteria is indicated, above all, in severe cases or cases presenting with invasive diarrhea. Viral detection is useful in epidemic outbreaks and in children younger than 3 years. If diarrhea persists, testing for parasites should also be performed.⁶ In immunocompromised individuals, multiplex panels for simultaneous detection of bacteria, viruses and parasites can be useful.⁷

In children aged more than 2 years with severe or prolonged diarrhea and risk factors for *Clostridioides difficile*, stool should be tested for the bacterium and its toxins.⁵ The risk factors for *C. difficile* infection are⁸: prolonged hospitalization, previous antibiotherapy, treatment with proton pump inhibitors, immunosuppression, nasogastric tube feeding, ostomy, gastrointestinal surgery and inflammatory bowel disease.

Table 2 presents the indications for blood culture.⁷

What techniques are available for etiological diagnosis and what are their characteristics?

Diagnostic tests are selected based on their availability, the clinical and epidemiological context and the care setting. Table 3 presents the available tests and their characteristics. The samples of choice are stool or specimens collected using rectal swab.^{9–11}

What are the indications for a complete blood count and/or measurement of acute phase reactants to guide the etiological diagnosis?

In children with AGE, a complete blood count and determination of acute phase reactants (APRs) are indicated when the child presents with general malaise, moderate/severe dehydration, hemodynamic instability or signs of sepsis.^{5,6} Routine performance of complete blood counts is not recommended for etiological investigation, although in some cases it may help to differentiate between viral and bacterial infections: leukocytosis with neutrophilia is suggestive of a bacterial etiology, and lymphocytosis or monocytosis of

a viral etiology. The complete blood count should be interpreted taking into account the clinical context, as its results may vary depending on the stage of the disease, patient age and nutritional status.

Levels of acute phase reactants, such as C-reactive protein (CRP) and procalcitonin (PCT), tend to be more elevated in the context of bacterial infection.¹ Procalcitonin is more sensitive and specific for differentiation of inflammatory and non-inflammatory diarrhea.¹² However, intermediate levels (20–70 mg/L for CRP and 0.25–0.50 ng/mL for PCT) may occur in both viral and bacterial infections. Furthermore, infection by adenovirus can cause CRP elevation.¹³ Among the available rapid diagnostic techniques (Table 3), some are used for detection of specific causative agents and others for markers that can help differentiate between a potential bacterial or viral etiology, for instance, myxovirus resistance protein A (MxA), whose levels increase specifically in active viral infections.^{14,15} Rapid tests are available to measure CRP and MxA in a single capillary blood sample by means of immunofluorescence. They may be useful when CRP or PCT levels are in the intermediate range or in viral infections with CRP elevation.¹⁶ While promising, they are still not widely used in clinical practice and further studies are needed before their widespread application can be recommended.

Fecal biomarkers such as calprotectin, lactoferrin, myeloperoxidase, leukocytes and occult blood are associated with bacterial pathogens.^{17,18} However, they are of limited utility in clinical practice and not usually recommended for etiological diagnosis.^{1,7,19}

Emerging pathogens and organisms of unclear pathogenicity

What is an emergent pathogen? What is an organism of unclear pathogenicity?

Emerging pathogens are not endemic in Spain, but their incidence is increasing due to sociodemographic and/or environmental changes. Microorganisms of unclear pathogenicity are those that are usually commensal, but under certain conditions (which depend on the organism or host) can cause symptoms directly or indirectly (dysbiosis).

Table 3 Diagnosis: diagnostic tests.

Test	Characteristics	Advantages	Disadvantages
<i>Stool culture</i>	Traditional diagnostic method for bacterial culture.	Allows performance of antimicrobial susceptibility testing.	Turnaround time longer than 48–72 hours.
<i>Rapid detection tests:</i>	Microbial antigens are detected and quantified using immunological techniques.	They enable very rapid diagnosis in the microbiology laboratory or, if available, at the point of care, which can guide treatment and allow identification and control of outbreaks.	Sensitivity lower than PCR. Does not allow performance of antimicrobial susceptibility testing.
1.- EIA, ELISA type		EIAs have a high sensitivity and specificity, although lower compared to PCR.	Labor-intensive technique that requires multiple reagents, washing steps and incubation times. However, there are membrane-based EIAs that are easier to use, as they do not require specialized equipment or personnel.
2.- IF		Good sensitivity and specificity, although lower compared to PCR.	The traditional IF technique is labor-intensive and costly, in addition to requiring the use of a fluorescence microscope. Currently, there are simpler techniques with automated readers. They are only useful for certain pathogens, such as rotavirus, adenovirus, <i>Giardia</i> , <i>Cryptosporidium</i> , <i>Entamoeba</i> and <i>C difficile</i> toxins A and B. Lower sensitivity compared to ELISA or PCR.
3.- IC	IC is the most widely used rapid diagnostic technique.	Qualitative technique, very quick and easy. No special laboratory equipment required. Very useful in cases of suspected viral AGE (caused by rotavirus, adenovirus, astrovirus, norovirus, and enterovirus) or AGE caused by certain parasites (<i>Giardia</i> , <i>Entamoeba</i> and <i>Cryptosporidium</i>) or bacteria (<i>Campylobacter</i> , <i>Salmonella</i> , <i>Shigella</i> and <i>C difficile</i> [toxin A and toxin B]).	
<i>Fresh stool examination</i>	When parasites are the suspected cause of diarrhea, microscopic examination allows direct observation of eggs, cysts and larvae.	Rapid technique.	It is observer/dependent. It has a low sensitivity. To increase it, three stool samples must be collected on alternate days.

Table 3 (Continued)

Test	Characteristics	Advantages	Disadvantages
<i>Molecular techniques (PCR)</i>	Use of syndromic panels that allow simultaneous detection of the nucleic acid of the main viruses, bacteria and parasites that cause diarrhea.	High sensitivity, superior to other diagnostic tests: they identify a greater number of pathogens and co-infections. Rapid technique (1–2 hours). Allow for the identification and control of outbreaks due to their speed. Reduce the inappropriate use of antibiotics. In hospitalized patients, they shorten the length of stay and reduce the prescription of antibiotics on discharge.	More expensive technique than the other techniques and not available in all laboratories. Since they may detect multiple pathogens, the clinical significance of some of them may be uncertain. Nucleic acid detection does not distinguish between colonization and asymptomatic carriage or whether the identified organisms are viable (possible persistence of nucleic acid after disease resolution). Does not allow for antimicrobial susceptibility testing.
<i>Serology</i>		Useful in very select patients with suspected parasitic infection by <i>Strongyloides stercoralis</i> , as microscopic examination offers a very low sensitivity.	

EIA, enzyme immunoassay; IA, immunoassay; IC, immunochromatography; IF, immunofluorescence; PCR, polymerase chain reaction.

When are microorganisms of unclear pathogenicity clinically relevant?

A review published by Weller et al. in 2023²⁰ identified numerous nonpathogenic protozoans (*Endolimax nana*; *Entamoeba* spp [*Entamoeba coli*, *E. bangladeshi*, *E. dispar*, *E. gingivalis*, *E. hartmanni*, *E. polecki*, *E. moshkovskii*]; *Iodamoeba buetschlii*; *Chilomastix mesnili*; *Pentatrichomonas hominis*). When detected in children with AGE, they should not be interpreted as the causative agent and the etiological investigation should continue. The use of molecular techniques is recommended to differentiate them from *Entamoeba histolytica*, which is pathogenic.

Other microorganisms of unclear pathogenicity may be present in carriers and cause acute or chronic diarrhea at some point, so their role must be investigated on a case-by-case basis for the purpose of treatment. The most frequent ones are *Enterocytozoon bieneusi* (microsporidian parasite), *Blastocystis* spp, *Dientamoeba fragilis*, *Cryptosporidium* spp or cytomegalovirus. *Clostridioides difficile* is considered commensal in the first 2 years of life.²¹ Table 4 details the conditions under which treatment would be indicated as well as the recommended drugs.

Which microorganisms, including emerging ones, should be considered in acute gastroenteritis in the context of travel?

There is a wide variety of reasons why individuals move from one geographical location to another (travel, migra-

tion, seeking asylum/refuge, international adoption). Thus, in the case of AGE in immigrant children, it is important to consider the particularities of both the host (malnutrition, incomplete vaccination, exposure to adverse environmental conditions, armed conflict or institutionalization and the associated risk factors) and the causative agent (potential for mixed infection, probability of antimicrobial resistance, endemic pathogens and variation in prevalence according to the region the child comes from). We ought to mention the following organisms:

- Bacteria: they are the most frequent cause of traveler's diarrhea (80%–90%).²² The most important ones are enterotoxigenic *Escherichia coli* (Latin America, Africa, Asia) and enteroinvasive *E. coli* (Latin America, Southeast Asia), followed by *Campylobacter* spp (Asia), *Salmonella* spp (Africa), *Shigella* spp (Latin America, Africa), *Vibrio cholerae* (poor sanitation, war zones).^{22–24}
- Viruses: chiefly rotavirus, in addition to adenovirus, norovirus, astrovirus, enterovirus.^{22,24}
- Parasites: less frequently involved, they should be considered in the case of prolonged travel or travel to endemic regions. We ought to mention *Giardia lamblia* (the most frequently involved parasite in traveler's diarrhea), *Cryptosporidium* spp, *Cyclospora* spp, *Strongyloides* spp (Southeast Asia), *Schistosoma* spp (Sub-Saharan Africa, Nile basin, Middle East), *Entamoeba histolytica* (Sub-Saharan Africa).^{22–24}

Infections by other microorganisms that may include diarrhea among their manifestations should be considered due

Table 4 Treatment according to the etiological agent: microorganisms of unclear pathogenicity and emerging pathogens.

Adjust according to antibiogram, with preferential selection of the narrowest possible spectrum and oral formulations, provided there are no contraindications

Pathogen	Indication for treatment	Treatment options	Dose	Duration
Microorganisms of unclear pathogenicity				
<i>Blastocystis</i> spp	- Only microorganism detected in stool and persistent diarrhea	Metronidazole	15 to 40 mg/kg/day/PO/every 8 h (max250 mg/dose)	5–7 days
		Paromomycin PO TMP/SMX PO	25 to 35 mg/kg/day/PO/every 6–12 h <12 years: 8–10/40–60 mg/kg/day/every 12 h >12 years: 160/800 mg/every 12 h	7 days 7 days
		Nitazoxanide PO (foreign drug use)	1–3 years: 100 mg/every 12 h 4 to 11 years: 200 mg/every 12 h ≥ 12 years: 500 mg/every 12 h	3 days
Cytomegalovirus	- Immunocompromised status - Inflammatory bowel disease	Ganciclovir IV	5–7.5 mg/kg/every 12 h	2–3 weeks
		Valganciclovir PO (if patient's condition allows it)	900 mg/every 12 h <16 years: dose calculation based on body surface area and creatinine clearance (see summary of product characteristics)	
<i>Clostridioides difficile</i>	- Recent antibiotic therapy and prolonged hospitalization, only in the case of prolonged/severe disease - cystic fibrosis - Immunodeficiency - Inflammatory bowel disease	Discontinue previous antibiotic		10 days
	Metronidazole ^a PO	7.5 mg/kg/dose/every 6–8 h		
	Vancomycin PO ^a	10 mg/kg/dose/every 6 h (max 125mg/dosis)		

Table 4 (Continued)

Adjust according to antibiogram, with preferential selection of the narrowest possible spectrum and oral formulations, provided there are no contraindications

Pathogen	Indication for treatment	Treatment options	Dose	Duration
<i>Cryptosporidium</i> spp.	Severe or fulminant infection Metronidazole IV + vancomycin PO	10 mg/kg/dose/every 8 h (max500 mg/dose) 10 mg/kg/dose/every 6 h (max500 mg/dose) Fidaxomicin VO	10 days Consider therapeutic drug monitoring	
	- High risk of recurrence or complications (Assess as first choice)		40–200 mg (based on weight)/every 12 h (see AEMPS summary of product characteristics)	10 days
	- Only microorganism detected in stool and persistent diarrhea - Immunocompromised status	Paromomycin PO	25 to 35 mg/kg/day/every 6–12 h	7 days
		Nitazoxanide PO (<i>foreign drug</i>)	1–3 years: 100 mg/every 12 h 4 to 11 years: 200 mg/every 12 h ≥ 12 years: 500 mg/every 12 h	3 days
<i>Dientamoeba fragilis</i>	- Only microorganism detected in stool and persistent diarrhea	Paromomycin PO	25 to 35 mg/kg/day/every 6–12 h	7 days
<i>Microsporidium: Encephalitozoon intestinalis</i> <i>Enterocytozoon bieneusi</i>	- Patients with HIV	Metronidazole PO Albendazole PO	40–50 mg/kg/day/every 6–8 h 400 mg/every 12 h	10 days 3 weeks
	- Immunocompromised status			
Emerging pathogens		Fumagillin PO	20 mg/every 8 h	14 days
<i>Balantidium coli</i>	- Whenever it is detected	Tetracycline (first-line for age >8 years, contraindicated for <8 years) Metronidazole PO	40 mg/kg/day/every 6 h (max2 g/d) 35–50 mg/kg/day/every 8 h Adult dose: 500–750 mg/every 8 h	5 days 5 days
		Iodoquinol PO (after meals)	30–40 mg/kg/day/every 8 h (max650 mg/dose)	20 days. If needed, another cycle can be administered after 2–3 weeks.

Table 4 (Continued)

Adjust according to antibiogram, with preferential selection of the narrowest possible spectrum and oral formulations, provided there are no contraindications

Pathogen	Indication for treatment	Treatment options	Dose	Duration
<i>Cyclospora cayetanensis</i>	- Immunocompromised status - Prolonged diarrhea - High risk of transmission (nursery, residential facilities)	TMP/SMX PO	2 months/18 years: 8–10 mg/kg TMP + 40–50 mg/kg SMX/every 12 h Adult doses: 160 mg TMP/800 mg SMX/every 12 h	7–10 days (patients with HIV may require a longer course)
<i>Cystoisospora belli</i>	- Immunocompromised status - Prolonged diarrhea	TMP/SMX l PO (first-line)	10 mg/kg/day TMP +50 mg/kg/day SMX/every 12 h	10 days
		Pyrimethamine PO + folic acid	50–75 mg/day/every 12 h 10–25 mg/day	14 days
<i>Entamoeba histolytica</i>	- Whenever it is detected	In symptomatic patients, use a tissue amebicide (metronidazole PO) followed by an intraluminal amebicide (paromomycin, iodoquinol). In asymptomatic patients, the described intraluminal amebicide suffices	Metronidazole: 40–50 mg/kg/day/PO/every 6–8 h (max1.5 g/day)	10 days
			Paromomycin: 25–35 mg/kg/day/PO/every 8 h	7 days
<i>Plesiomonas</i>	- Severe forms	TMP/SMX PO	40–60/8–10 mg/kg/day/PO/every 12 h (max 1600/320 mg/day)	3–5 days
<i>Salmonella typhi</i>	- Whenever it is detected	Third-generation cephalosporins	100–200 mg/kg/day/IV/every 6–8 h (max12 g/day)	7 days
		TMP/SMX	Cefotaxime Other cephalosporins, consult Pediamécum. 40–60/8–10 mg/kg/day/PO/every 12 h (max 1600/320 mg/day)	3–5 days
		Ciprofloxacin	30 mg/kg/day/PO/every 12 h (max recommended for treatment of AGE, 1 g/day). <i>Off-label use in pediatric population</i>	3–5 days

Table 4 (Continued)

Adjust according to antibiogram, with preferential selection of the narrowest possible spectrum and oral formulations, provided there are no contraindications

Pathogen	Indication for treatment	Treatment options	Dose	Duration
<i>Schistosoma</i> (<i>S. mansoni</i> , <i>S. japonicum</i> , <i>S. intercalatum</i> , <i>S. mekongi</i> , <i>S. haematobium</i> - <i>S. bovis</i> hybrids)	- Whenever it is detected.	Praziquantel PO	- <i>S. mansoni</i> , <i>S. intercalatum</i> , <i>S. haematobium</i> : 20 mg/kg/every 12 h	1 day
<i>Strongyloides stercoralis</i>	- Whenever it is detected	Ivermectin PO (first-line). Its use for weight <15 kg is controversial. Contraindicated for age <2 years Albendazole PO (>2 years)	- <i>S. japonicum</i> , <i>S. mekongi</i> : 20 mg/kg/every 8 h 200 µg/kg: - 15–24 kg: 1 tablet every 24 h - 25–35 kg: 2 tablet/ every 24 h - 35–50 kg: 3 tablet/ every 24 h - 51–65 kg: 4 tablet/	1–2 days (2 days in immunocompromised)
<i>Trichuris trichiura</i>	Whenever it is detected	Mebendazole PO (first-line) Albendazole PO	400 mg/every 12 h 100 mg/every 12 h o 500 mg single dose (a) 1–2 years: - mild/moderate: 200 mg single dose - severe: 1 st dose 200 mg, following doses 100 mg every 12 h (b) >2 years: - mild/moderate: 400 mg single dose - severe: 400 mg/day	7 days Repeat cycle monthly for 3 months 3 days 3 days
<i>Vibrio cholerae</i>	- Always, even on the sole basis of epidemiological suspicion	Ivermectin PO Azithromycin (first-line)	150–200 µg/kg every 24 h 10 mg/kg/day/PO/every 24 h (max 500 mg/day)	3 days 3–5 days
		TMP/SMX	40–60/8–10 mg/kg/day/PO/every 12 h (max 1600/320 mg/day)	3–5 days
		Doxycycline (>8 years)	2–4 mg/kg/day/PO/every 12–24 h (max 200 mg/day)	5–7 days

AEMPS, Spanish Agency of Medicines and Medical Devices (*Agencia Española de Medicamentos y Productos Sanitarios*); EHEC, enterohemorrhagic *E. coli*; EPEC, enteropathogenic *E. coli*; ETEC, enterotoxigenic *E. coli*; h, hours; HUS, hemolytic uremic syndrome; IM, intramuscular route; IV, intravenous route; PO, oral route; TMP/SMX, trimethoprim/sulfamethoxazole.

Useful link: Pediamécum: <https://www.aeped.es/comite-medicamentos/pediamecum>.

^a For primary infection, see references for the treatment of recurrence.

to their clinical significance, even if their presentation is different (hepatitis A virus; human immunodeficiency virus; dengue virus, *Plasmodium* spp).

Etiological treatment

Under which conditions is empiric antimicrobial treatment indicated for acute gastroenteritis?

In healthy children in Spain, AGE is a self-limiting disease in most cases, independently of its etiology.⁴ Complications are infrequent, except in the first two years of life, due to the immaturity of the child's immune system, metabolism and bowel function, combined with the high nutritional requirements.^{6,25}

Most cases of AGE have a viral etiology and manifest with watery (non-invasive) diarrhea, and therefore do not require antimicrobial treatment.^{4,6,7,26} Some guidelines contemplate an exception in patients presenting with watery diarrhea and high fever following international travel to cholera-endemic regions.^{7,26}

When it comes to AGE of a suspected bacterial etiology (invasive features), certain considerations must be kept in mind:

- A) In general, routine use of antibiotherapy is not indicated.^{4,7,25-27}
- B) A review of the current literature shows a high level of consensus regarding the conditions under which empiric antibacterial treatment is indicated^{4,26,27}: host-related factors (age, comorbidities), clinical presentation, epidemiological factors and suspicion of specific pathogens (see Tables 4 and 6).^{4,7,25-27}
 - none- Age: there is consensus regarding the need to treat AGE of suspected bacterial etiology in infants aged less than 3 months, although some authors extend the recommendations to 6 months of age.^{4,7,25-27}
 - none- Underlying disease: immunocompromised status, asplenia, severe chronic illness, sickle cell disease or malnutrition are indications for initiation of empiric antibiotherapy.^{4,7,25}
 - none- Clinical presentation: in the presence of clinical features suggestive of sepsis, empiric therapy would be indicated based on the suspected causative agent.^{7,27,28}
 - none- Epidemiological factors: patients in residential facilities, due to the risk of transmission.^{26,27}
 - none- If empiric treatment is initiated according to the aforementioned criteria, the first-line agents are oral azithromycin or parenteral third-generation cephalosporins.²⁵
- C) Traveler's diarrhea: up to 80%–90% of cases have a bacterial etiology.^{22,27} Fig. 1 proposes an algorithm for its management.

In general, and given the emerging problem of antimicrobial resistance, the routine use of anti-infective drugs is not justified.

When is antibiotherapy contraindicated in acute gastroenteritis of bacterial etiology?

Nontyphoidal *Salmonella*

In these cases, antibiotherapy in healthy children does not shorten the duration of fever or diarrhea compared to placebo or no treatment.

In children aged less than 5 years, the median duration of excretion is 7 weeks, with 2.6% of patients continuing to shed the bacterium for a year or longer. In chronic carriers, *Salmonella* is typically found in the biliary tract and is frequently associated with cholelithiasis. Historically, there has been a widespread belief that antimicrobial treatment of AGE caused by nontyphoidal *Salmonella* is associated with protracted shedding, although this has been recently questioned.²⁸ There is also evidence suggesting that antibiotherapy in the context of chronic intestinal carriage may promote extraintestinal spread with bacteremia, produce symptomatic relapse or encourage the development or selection of resistant strains.²⁹

Therefore, in uncomplicated cases of gastroenteritis caused by nontyphoidal *Salmonella* (except in patients with prolonged diarrhea), antibiotic treatment is not recommended, and its indications are limited to cases of prolonged diarrhea and individuals at risk of systemic infection: extreme age (<3–6 months), current steroid therapy, lymphoproliferative disease, inflammatory bowel disease, immunocompromised status/immunosuppression, hemoglobinopathy (sickle cell anemia), hemodialysis.²⁹

Shiga toxin-producing *Escherichia coli*

Only a small proportion (5%–10%) of children with infection by Shiga toxin-producing *Escherichia coli* (STEC), generally aged less than 5 years, develop hemolytic uremic syndrome (HUS). This is characterized by the triad of hemolytic anemia, thrombocytopenia and acute kidney injury and is most frequently associated with *E coli* O157:H7.

The association between the use of antibiotics and the development of HUS remains controversial. Evidence from numerous studies suggests that some antibiotics may increase the risk of HUS, while others may not have any effect on the risk or may even reduce it. Beta-lactam antibiotics and trimethoprim-sulfamethoxazole may be harmful,³⁰ but other agents, such as fosfomycin, appear safe and may prevent HUS in adult patients, especially if they are administered in the first days after onset of diarrhea.³¹ Fluoroquinolones have also been found to achieve positive outcomes in adults, in spite of some unfavorable in vitro studies. Colistin, gentamicin and rifamycins have shown promising results in vitro.³¹ Other drugs, such as azithromycin and rifaximin, do not appear to increase the production of Shiga toxin.²⁹ During the STEC O104:H4 outbreak in Germany in 2011, a study found that treatment with azithromycin was associated with a lower frequency of long-term STEC O104:H4 carriage.³² However, further studies are required to determine the safety of these antibiotic agents in patients with colitis caused by STEC. While awaiting such evidence, most societies currently recommend supportive care without antibiotherapy.¹




Figure 1 Algorithm for the management of AGE in the context of travel (international travel, adoption, migration, etc). ABX, antibiotherapy; BT, blood test; ETEC, enterotoxigenic *Escherichia coli*; IBS, irritable bowel syndrome; PE, physical examination; RF, risk factor; Tx: treatment; wk, weeks; h, hours. Algorithm adapted from: Badillo Navarro et al.²² and Imbert.³⁸

In consequence, in most cases of AGE of suspected bacterial etiology, antibiotherapy should not be initiated until the causative agent has been identified by means of PCR or stool culture. The exception are children who are severely ill, hemodynamically unstable or who have the aforementioned risk factors, in whom initiation of empiric antibiotherapy would be justified.

What are the criteria for hospital admission?

See Table 5.

Which treatment is indicated for each causative agent?

See Table 6.

Complications

Establishing the prevalence of the complications of AGE in Spain is challenging due to methodological limitations of study designs (isolated cases of rare complications, retrospective studies or studies with a low HDI, inclusion of

Table 5 Treatment: criteria for hospital admission.

By etiology or patient characteristics	Due to dehydration, risk of dehydration or metabolic disorder
- Severely immunocompromised status - Severe or systemic infection requiring intravenous antibiotherapy - Infants under 3–6 months with gastroenteritis due to nontyphoidal <i>Salmonella</i> - Failure of oral treatment	- Oral intolerance, impossibility or failure of oral rehydration (due to refusal, social situation, or vomiting); uncontrollable or bilious vomiting - Neurologic symptoms (altered consciousness, lethargy, seizures) - Any contraindications to oral rehydration, chiefly: •Severe dehydration (equal to or greater than 9%) •Hemodynamic instability. Shock. Sepsis •Decreased level of consciousness •Paralytic ileus or suspected acute abdomen •Uncertain diagnosis, with potential need for urgent surgery

hospitalized patients, etc) and the lack of guidelines on their management based on the etiology.

What is the most frequent and the most severe complication of acute gastroenteritis?

The most frequent complication of AGE is dehydration. Moderate to severe diarrhea (MSD) is more frequent in cases of AGE caused by rotavirus, *Cryptosporidium* spp, enterotoxigenic *E coli* and *Shigella* spp.³³ Development of MSD increases mortality by 8.5-fold compared to healthy children of the same age and sex, chiefly in children younger than 2 years.³³ However, the mortality associated with MSD in Europe is very low (<1 death/100 000 inhabitants/year in children aged less than 5 years).³ Chronic malnutrition increases the likelihood of DMG and the risk of additional episodes.

However, up to two-thirds of deaths from MDG are unrelated to dehydration during the acute phase and occur more than 7 days later.³³ Despite this, no treatment based on nutritional supplements (zinc or vitamin A), probiotics, oral rehydration solutions or antibiotics has any effect on mortality, worsening nutritional status or the persistence of diarrhea.³⁴

What is post-enteritis syndrome?

Most studies on post-enteritis syndrome, also referred to as post-infectious irritable bowel syndrome (IBS) or persistent diarrhea (PD), have been conducted in countries with a low HDI, so their generalization to everyday clinical practice in Spain is complicated. Although there is no consensus on its correct definition, it is generally defined as diarrhea lasting more than 7 days.

Little is known about its etiology, which involves the presence of persistent infection, changes in the intestinal microflora, mucosal permeability, carbohydrate malabsorption (secondary lactose intolerance), food allergy (chiefly cow's milk protein allergy), dysmotility or the presence and persistence of malnutrition enteropathy.³⁵

In countries with high HDI, an association has been found between the severity of AGE and the presence of PD, unrelated to the causative agent or changes in the microbiome.³⁶

The use of novel molecular diagnostic techniques could yield more information on the infectious etiology of PD.³⁷

What are the complications of acute gastroenteritis depending on the causative agent?

The incidence of systemic complications is low. Infants (aged less than 3 months), immunocompromised individuals, malnourished individuals or individuals with underlying diseases are most vulnerable.

Table 7 summarizes specific complications by pathogen and risk group.

Recommendations

Diagnosis

- none– Microbiological testing is only indicated in certain cases of AGE (Table 2) (94.4% consensus).
- none– Selective investigation of microorganisms taking into account the clinical presentation and epidemiological context: bacteria chiefly in patients with severe disease or dysenteric diarrhea; viruses in epidemic outbreaks and in children younger than 3 years; parasites in cases of prolonged diarrhea (100% consensus).
- none– The following factors should be considered when selecting the diagnostic method: availability, advantages and disadvantages of each test (Table 3), and the clinical presentation and epidemiological context of the patient. (100% consensus).
- none– The complete blood count and APR levels are of little value for differentiating between viral and bacterial etiologies; they would only be indicated in patients with constitutional symptoms (100% consensus).

Emerging pathogens and organisms of unclear pathogenicity (100% consensus)

- none– The role of microorganisms of unclear pathogenicity has to be assessed in each case.
- none– In cases of AGE in the context of migration, we recommend assessing the particular characteristics and

Table 6 Treatment according to the etiological agent: prevalent pathogens.

Adjust according to antibiogram, with preferential selection of the narrowest possible spectrum and oral formulations, provided there

are no contraindications

Pathogen	Indication for treatment	Treatment options		Dose	Duration
<i>Aeromonas</i> spp	- Persistent diarrhea (rare) - Chronic forms (rare) - Severely immunocompromised status	TMP/SMX	Cefixime	8 mg/kg/day/PO/every 12 h (max 400 mg/day). <i>Off-label use.</i> 3–5 days	3–5 days
<i>Campylobacter</i> spp	- High risk of transmission (nursery, residential facilities) - Immunocompromised status - Persistent diarrhea (>7 days)	Ciprofloxacin	Azithromycin (first-line)	10 mg/kg/day/PO /every 24 h (max 500 mg/day) 3–5 days	3–5 days
	- Severe or systemic infection (bacteremia):		Meropenem	3 months–11 years (< 50 kg): 10–20 mg/kg every 8 h > 11 years and 50 kg: 500 o 1000–mg every 8–h	14 days
			Imipenem/cilastin	Consult Pediamécum (Adjuvants to the above)	14 days
			Cefotaxime (with confirmed sensitivity)	100–200 mg/kg/day /IV/every 6–8 h (max 12 g/day)	7 days
			Ceftriaxone (with confirmed sensitivity)	50–75 mg/kg/day, IM/IV/every 24 h (max 4 g/day)	3–5 days
			Aminoglycosides (Adjuvants to the above)	5–7.5 mg/kg/day/IV, every 24 h. Monitor drug levels. Rarely used for AGE. Consult Pediamécum.	3–5 days
			Other	Consult Pediamécum.	
<i>Escherichia coli</i>	- EPEC and ETEC: if prolonged/severe course; traveler's diarrhea that is not self-limited - EHEC (O157:H7): contraindicated, increases risk of HUS		Azithromycin (first-line)	10 mg/kg/day/PO /every 24 h (max 500 mg/day)	3–5 days

Table 6 (Continued)

Adjust according to antibiogram, with preferential selection of the narrowest possible spectrum and oral formulations, provided there are no contraindications

There are no contraindications			TMP/SMX	40–60/8–10 mg/kg/day/PO/every 12 h (max 1600/320 mg/day)	3–5 days	
			Ciprofloxacin	30 mg/kg/day/PO/every 12 h (max recommended for treatment of AGE, 1 g/day). <i>Off-label use in pediatric population.</i>	3–5 days	
<i>Giardia lamblia</i>	- Prolonged/severe disease	Metronidazole		15 mg/kg/day/PO/every 8 h (max1.5 g/day).	5–7 days	
		Nitazoxanide (Foreign drug)			PO, 1–3 years: 100 mg/every 12 h; 4–11 years: 200 mg every 12 h; >12 years: 500 mg/every 12 h (max1 g/day).	3 days
		Albendazole			PO, usual dose of 200 mg/every 12 h (max400 mg/day). <i>Off-label use.</i>	3–5 days
<i>Nontyphoidal Salmonella</i>	Severe or systemic infection, and groups at risk of it: - Infants younger than 3–6 months (risk of bacteremia) - Immunocompromised status - Use of steroids - Lymphoproliferative disorders - Inflammatory bowel disease - Hemoglobinopathies (sickle cell anemia) - Hemodialysis - Persistent diarrhea (>7 days) Note: Some authors recommend not treating in any case. If treating: although there are concerns that it can prolong carriage, current scientific evidence does not support this claim.	Third-generation cephalosporins (first-line)	Cefotaxime	100–200 mg/kg /day/IV/every 6–8 h (max12 g/day).		
					In infections of the CNS, 200–300 mg/kg/day /every 6–8 h (max12 g/day). Consult Pediamécum	See complications
				Other cephalosporins		
			Amoxicillin (alternative if sensitivity is confirmed)		40–45 mg/kg/day/PO/every 8 h (max500 mg/dose)	7 days
			Ampicillin (alternative if sensitivity is confirmed)		100 mg/kg/day/ /IV/every 6 h.	7 days

Table 6 (Continued)

Adjust according to antibiogram, with preferential selection of the narrowest possible spectrum and oral formulations, provided there are no contraindications

Amoxicillin/clavulanic acid (alternative) Note: Recommended by some authors and experts due to the increasing resistance to ampicillin and amoxicillin	PO: 50 mg/kg/day, every 8 h (max recommended for treatment of AGE, 3 g/day of amoxicillin, not exceeding 375 mg/day of clavulanic acid). Check the different ratios of clavulanic acid in Pediamécum. IV: 100 mg/kg/day/every 6–8 h (max recommended for treatment of AGE, 3 g/day of amoxicillin, not exceeding 375 mg/day of clavulanic acid). Check the different ratios of clavulanic acid in Pediamécum	7 days
Azithromycin (alternative)	10 mg/kg/day/PO/every 24 h (max 500 mg/day)	3–5 days
TMP/SMX (alternative if sensitivity is confirmed)	40–60/8–10 mg/kg/day/PO/every 12 h (max 1600/320 mg/day).	3–5 days
	8–12 mg/kg/day trimethoprim/IV/every 12 h (max 160 g trimethoprim/dose)	See complications
Ciprofloxacin (alternative)	30 mg/kg/day, PO, every 12 h (max recommended for treatment of AGE, 1 g/day). <i>Off-label use in pediatric population.</i>	3–5 days

Table 6 (Continued)

Adjust according to antibiogram, with preferential selection of the narrowest possible spectrum and oral formulations, provided there are no contraindications

COMPLICATIONS	Bacteremia	<3 months	Third-generation cephalosporins (first-line) Cefotaxime Ceftriaxone Alternatives: quinolones or TMP-SMX, always considering the clinical condition and the antibiogram results.	10 mg/kg/IV/every 8–12 h (max400 mg/dose)	See complications
				IV treatment Analyze CSF in every case	10 days
		3–12 months		IV treatment CSF if clinically indicated.	7 days
		>12 months		CSF if clinically indicated. IV treatment. Possibility of switching to PO depending on course of disease	7 days
	Meningitis			(amoxicillin, amoxicillin-clavulanic acid, TMP/SMX or azithromycin)	
				IV treatment (until completion) Consider adding ciprofloxacin in severely ill children awaiting susceptibility results or if CSF culture growth persists after 48–72 hours.	4–6 weeks
Shigella spp	- Always, even on the sole basis of epidemiological suspicion		Third-generation cephalosporins (first-line) Other cephalosporins	Cefotaxime	4–6 weeks
				100–200 mg/kg/day/IV/every 6–8 h (max12 g/day).	
				Maintain IV treatment for at least 3 weeks	7 days
		Azithromycin		Consult Pediamécum. 10 mg/kg/day/PO/every 24 h (max500 mg/day)	3–5 days

Table 6 (Continued)

Adjust according to antibiogram, with preferential selection of the narrowest possible spectrum and oral formulations, provided there are no contraindications

Yersinia spp	- Persistent infection and symptoms - Immunocompromised status - Severe or systemic infection Note: some authors recommend not treating in any case.	Ciprofloxacin	30 mg/kg/day, PO, every 12 h (max recommended for treatment of AGE, 1 g/day). <i>Off-label use in pediatric population.</i>	3–5 days	
		TMP/SMX Note: if the isolated strains are susceptible or local microbiological data suggestive of susceptibility	40–60/8–10 mg/kg/day, PO, every 12 h (max 1600/320 mg/day)	3–5 days	
		Third-generation cephalosporins			
		Cefotaxime	100–200 mg/kg/day/IV/every 6–8 h (max 12 g/day) Other cephalosporins	7 days	
		Aminoglycosides Gentamicin	5–7.5 mg/kg/day/IV/every 24 h. Monitor drug levels. Rarely used for treatment of AGE.	Consult Pediamécum.	3–5 days
		TMP/SMX		Other aminoglycosides: consult Pediamécum	3–5 days
		Ciprofloxacin		40–60/8–10 mg/kg/day/PO/every 12 h. Max 1600/320 mg/day. 30 mg/kg/day, PO, every 12 h (max recommended for treatment of AGE, 1 g/day). <i>Off-label use in pediatric population.</i>	3–5 days

AEMPS, Spanish Agency of Medicines and Medical Devices (*Agencia Española de Medicamentos y Productos Sanitarios*); EHEC, enterohemorrhagic *E coli*; EPEC, enteropathogenic *E coli*; ETEC, enterotoxigenic *E coli*; h, hours; HUS, hemolytic uremic syndrome; IM, intramuscular route; IV, intravenous route; PO, oral route; TMP/SMX, trimethoprim/sulfamethoxazole.
Useful link: Pediamécum: <https://www.aeped.es/comite-medicamentos/pediamecum>.

Table 7 Complications by etiological agent.

Microorganism	Complication
Rotavirus	Severe disease, febrile seizures (2%–8%), benign convulsions with mild diarrhea (4%), encephalitis, meningitis, cerebellitis, necrotizing enterocolitis, intussusception, Gram-negative bacteremia
Norovirus	Seasonal outbreaks, febrile seizures and benign convulsions with mild diarrhea, severe disease ^a , persistent diarrhea ^a
Adenovirus	Severe disease ^a , persistent diarrhea ^a , hepatitis
<i>Salmonella</i> (<i>S enteritidis</i> and <i>typhimurium</i>)	Bacteremia (1%) ^{a,b,c} , endocarditis ^c , endovascular infection ^d , osteomyelitis ^e , septic arthritis, reactive arthritis ^f , meningitis, brain abscess, urinary tract infection, visceral involvement (pulmonary, pleural, hepatic or splenic)
<i>Shigella</i> spp	Bacteremia (4%), convulsive seizures and/or encephalopathy (up to 40%), reactive arthritis ^f , rectal prolapse, toxic megacolon, intestinal obstruction, colonic perforation, leukemoid reaction.
<i>Yersinia</i> spp	Bacteremia, pharyngitis and pharyngeal abscess, pseudoappendicitis, ileitis, intestinal perforation, peritonitis, intussusception, toxic megacolon, intestinal ischemia, cholangitis, mesenteric vein thrombosis, visceral abscess (liver, spleen, kidney, or lung), endocarditis, septic arthritis, reactive arthritis ^f , skin manifestations (erythema nodosum ^f), uveitis, conjunctivitis.
<i>Campylobacter</i> spp	Severe disease ^g , pseudoappendicitis, colitis, lymphoma, cholecystitis, peritonitis, erythema nodosum ^f , cellulitis, reactive arthritis, septic arthritis, osteomyelitis, pseudoaneurysm, pericarditis, myocarditis, Guillain-Barré syndrome ^f , Miller-Fisher syndrome ^f
Shiga toxin-producing <i>E coli</i>	Hemolytic-uremic syndrome
<i>Clostridioides difficile</i>	Severe disease, pseudomembranous colitis, fulminant colitis, bacteremia, reactive arthritis ^f , recurrent disease
<i>Giardia lamblia</i>	Chronic diarrhea with malabsorption, malnutrition, aphthous stomatitis, urticaria, irritable bowel syndrome, chronic fatigue, cholecystitis, cholangitis, hepatitis, exocrine pancreatic insufficiency.
<i>Cryptosporidium</i> spp	Chronic diarrhea with malnutrition ^{a,g} , cholecystitis ^g , cholangitis ^g , hepatitis, pancreatitis, chronic symptoms (abdominal pain, joint pain, nausea, fatigue, headache, eye pain, anorexia, or weight loss)

Abbreviation: HIV, human immunodeficiency virus.

^a Immunocompromised status.

^b Age <1 year.

^c Users of prosthetics.

^d Arteriosclerosis.

^e Hemoglobinopathies.

^f Late post-infectious sequela.

^g HIV.

circumstances of the host, as they may affect the potentially involved microorganisms.

none– The empirical antibiotherapy approach for traveler's diarrhea depends on its characteristics, the patient's general condition, and the course of disease after 72 h, always considering the presence of risk factors.

Treatment. (100% consensus)

none– In the case of infection by *Salmonella* spp, antibiotherapy is only indicated in individuals at risk of systemic infection or cases of prolonged diarrhea.

none– The use of bactericidal agents for treatment of infection by STEC O157 may be associated with the development of HUS.

none– Due to the growing problem of antimicrobial resistance, the routine use of anti-infectives in AGE is

not advisable, and the use of these agents should be restricted to specific circumstances.

Complications. (100% consensus)

none– Although the incidence of complications is low, monitoring for their development is recommended in at-risk patients (children younger than 2 years of age, immunocompromised patients, malnourished patients) and in cases of moderate/severe AGE.

none– Ruling out lactose intolerance or CMPA is recommended in patients with prolonged diarrhea following AGE, assessing for nutritional disorders that may perpetuate it.

Annex 1: Members of the Working Group on Pediatric Acute Gastroenteritis

Belen Aguirrezabalaga González (SEPEAP), Ana María Alonso Rubio (SEPEAP), Rosario Bachiller Luque (SEPEAP), Alicia Berghezan Suárez (AEPap and SEIP), María Natali Campo Fernández (SEUP), Ángel José Carbajo Ferreira (AEPap), Antonio José Conejo Fernández (SEIP), Marta Cruz Cañete (SEIP), Ana Pilar Galera Peinado (AEPap), Parísá Khodayar-Pardo (SEUP), David López-Martín (SEIP), M. del Pilar Lupiani Castellanos (AEPap), Carlos Ochoa Sangrador (SEGHNP), Luis Ortiz González (SEPEAP), Begoña Pérez-Moneo (SEGHNP), Roi Piñeiro Pérez (SEIP), Ricardo Torres-Peral (SEGHNP) and Roberto Velasco Zuñiga (SEUP)

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.anpedi.2025.503984>.

References

- Guarino A, Ashkenazi S, Gendrel D, Lo Vecchio A, Shamir R, Szajewska H, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. *J Pediatr Gastroenterol Nutr.* 2014;59:132–52.
- Enfermedades diarreicas [Internet]. [Accessed 27 May 2025]. Available from: <https://www.who.int/es/news-room/fact-sheets/detail/diarrhoeal-disease>.
- GBD 2016 Diarrhoeal Disease Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Infect Dis.* 2018;18:1211–28.
- Guarino A, Lo Vecchio A, Dias JA, Berkley JA, Boey C, Bruzzese D, et al. Universal recommendations for the management of acute diarrhea in nonmalnourished children. *J Pediatr Gastroenterol Nutr.* 2018;67:586–93.
- Menasalvas Ruiz A, Medina Claros A, Álvarez Vallejo B. Diarrea infecciosa. Infecciones por *Clostridioides difficile*. *Protoc Diagn Ter Pediatr.* 2023;2:181–95.
- Carbajo Ferreira A., Rodríguez Delgado J. Diarrea aguda. En: *Guía de Algoritmos en Pediatría de Atención Primaria* [Internet]. [Accessed 25 November 2024]. Available from: <https://algoritmos.aepap.org/index.php>.
- Shane AL, Mody RK, Crump JA, Tarr PI, Steiner TS, Kotloff K, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. *Clin Infect Dis.* 2017;65:e45–80.
- Kimberlin D. American Academy of Pediatrics. *Clostridium difficile*. In: Kimberlin DW, Brady MT, Jackson MA, editors. *Long SS Red Book, Enfermedades Infecciosas en Pediatría*. 31st ed Ciudad de Mexico: Editorial Médica Panamericana; 2019. p. 296–300.
- Freedman SB, Xie J, Nettel-Aguirre A, Lee B, Chui L, Pang XL, et al. Enteropathogen detection in children with diarrhoea, or vomiting, or both, comparing rectal flocked swabs with stool specimens: an outpatient cohort study. *Lancet Gastroenterol Hepatol.* 2017;2:662–9.
- Johnstone SL, Page NA, Groome MJ, du Plessis NM, Thomas J. Diagnostic testing practices for diarrhoeal cases in South African public hospitals. *BMC Infect Dis.* 2022;22:827.
- Jean S, Yarbrough ML, Anderson NW, Burnham CA. Culture of rectal swab specimens for enteric bacterial pathogens decreases time to test result while preserving assay sensitivity compared to bulk fecal specimens. *J Clin Microbiol.* 2019;57:e02077–18.
- Shin HJ, Kang SH, Moon HS, Sung JK, Jeong HY, Kim JS, et al. Serum procalcitonin levels can be used to differentiate between inflammatory and non-inflammatory diarrhea in acute infectious diarrhea. *Medicine (Baltimore).* 2018;97:e11795.
- Thiruchelvam R, Ramakrishnan S, Krishnamoorthy N. Role of C-reactive protein in predicting adenoviral infections in children aged 1 month to 18 years. *ACH.* 2024;1:15–20.
- Engelmann I, Dubos F, Lobert PE, Houssin C, Degas V, Sardet A, et al. Diagnosis of viral infections using myxovirus resistance protein A (MxA). *Pediatrics.* 2015;135:e985–993.
- Piri R, Yahya M, Ivaska L, Toivonen L, Lempainen J, Nuolivirta K, et al. Myxovirus resistance protein A as a marker of viral cause of illness in children hospitalized with an acute infection. *Microbiol Spectr.* 2022;10:e0203121.
- Ridaio Redondo M, Puentes Amado A. Test de diagnóstico microbiológico rápido en la consulta de Pediatría de Atención Primaria. *Pediatr Integral.* 2023;XXVII:395–403.
- Park Y, Son M, Jekarl DW, Choi HY, Kim SY, Lee S. Clinical significance of inflammatory biomarkers in acute pediatric diarrhea. *Pediatr Gastroenterol Hepatol Nutr.* 2019;22:369–76.
- Patel HM, Kaur MR, Haris Ali M, Hadi Z, Parikh A, Khan SH, et al. Evaluation of non-invasive diagnostic tools for diarrhea: a systematic review of point-of-care tests and biomarkers. *Ann Med Surg (Lond).* 2024;86:2951–62.
- Ribes Koninckx C, Donat E, Benninga MA, Broekaert IJ, Gottrand F, Kolho KL, et al. The use of fecal calprotectin testing in paediatric disorders: a position paper of the European society for paediatric gastroenterology and nutrition gastroenterology committee. *J Pediatr Gastroenterol Nutr.* 2021;72:617–40.
- Weller P, Leder K. Nonpathogenic enteric protozoa. En: *UpToDate* [Internet]. [Accessed 17 September 2024]. Available from: www.uptodate.com.
- Shirley DA, Tornel W, Warren CA, Moonah S. *Clostridioides difficile* infection in children: recent updates on epidemiology, diagnosis, therapy. *Pediatrics.* 2023;152:e2023062307.
- Badillo Navarro K, Blázquez Gamero D, García Hortelano M. Diarrea del viajero, Available from: <https://www.guia-abe.es>, 2020.
- Abu-Shamsieh A, Maw S. Pediatric care for immigrant, refugee, and internationally adopted children. *Pediatr Clin North Am.* 2022;69:153–70.
- Oppong TB, Yang H, Amponsem-Boateng C, Kyere EKD, Abdulai T, Duan G, et al. Enteric pathogens associated with gastroenteritis among children under 5 years in sub-Saharan Africa: a systematic review and meta-analysis. *Epidemiol Infect.* 2020;148:e64.
- Bartolomé Porro J, Vecino López R, Rubio Murillo M. Diarrea aguda. *Protoc Diagn ter Pediatr.* 2023;1:99–108.
- de la Flor i Brú J. Gastroenteritis aguda. *Pediatr Integral.* 2019;XXIII:348–55.
- Bruzzese E, Giannattasio A, Guarino A. Antibiotic treatment of acute gastroenteritis in children. *F1000Res.* 2018;7:193.
- Leinert JL, Weichert S, Jordan AJ, Adam R. Non-typhoidal salmonella infection in children: influence of antibiotic therapy on postconvalescent excretion and clinical course-A systematic review. *Antibiotics (Basel).* 2021;10:1187.
- Ochoa T, Chea-Woo E. Approach to patients with gastrointestinal tract infections and food poisoning. In: Cherry JD, Demmler-Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ, editors. *Feigin*

- and Cherry's textbook of pediatric infectious diseases. 8th ed Philadelphia, Pensilvania: Elsevier; 2019. p. 458–9.
30. Smith KE, Wilker PR, Reiter PL, Hedican EB, Bender JB, Hedberg CW. Antibiotic treatment of *Escherichia coli* O157 infection and the risk of hemolytic uremic syndrome, Minnesota. *Pediatr Infect Dis J*. 2012;31:37–41.
31. Kakoullis L, Papachristodoulou E, Chra P, Panos G. Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview. *J Infect*. 2019;79:75–94.
32. Nitschke M, Sayk F, Härtel C, Roseland RT, Hauswaldt S, Steinhoff J, et al. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative *Escherichia coli* O104:H4. *JAMA*. 2012;307:1046–52.
33. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. *Lancet*. 2013;382:209–22.
34. Pavlinac PB, Brander RL, Atlas HE, John-Stewart GC, Denno DM, Walson JL. Interventions to reduce post-acute consequences of diarrheal disease in children: a systematic review. *BMC Public Health*. 2018;18:208.
35. Bandsma RHJ, Sadiq K, Bhutta ZA. Persistent diarrhoea: current knowledge and novel concepts. *Paediatr Int Child Health*. 2019;39:41–7.
36. Lo Vecchio A, Quitadamo P, Poeta M, Buccigrossi V, Siani P, Cioffi V, et al. Aetiology, risk factors and microbiota composition in children with prolonged diarrhoea: a prospective case-controlled cohort study. *Acta Paediatr*. 2024;113:598–605.
37. Liu J, Platts-Mills JA, Juma J, Kabir F, Nkeze J, Okoi C, et al. Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study. *Lancet*. 2016;388:1291–301.
38. Imbert P [Accepted 31 October 2024]. Available from: <https://pap-pediatrie.fr/immuno-infectio-parasito/diarrhee-au-retour-dun-pays-tropical>, 2014.